AstraZeneca (AZN) and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu (trastuzumab deruxtecan) in breast cancer.The regulatory body has now approved Enhertu as a monotherapy for treating metastatic HR-positive, HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for the therapy as the next line of treatment in the European Union (“EU”).The la ...

Group 1 - AstraZeneca achieved a remarkable 18% increase in revenue, reaching record levels in 2024 [1] - The growth in revenue was primarily driven by strong performance in key therapeutic areas [1] Group 2 - AstraZeneca is recognized as one of the pillars of the global pharmaceutical industry [1]

Signage at the AstraZeneca facility in Gaithersburg, Maryland, US, on Monday, Aug. 26, 2024. He said that leads to 4 million to 5 million deaths worldwide due to elevated cholesterol. While PCSK9 injections have helped treatment reach more patients, their use has still been "very limited," Makar said. That's due to several factors, such as challenges related to cost and access and hesitancy among some cardiologists and primary care physicians. "That's why we're really excited about our oral PCSK9," Makar sa ...

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F __ Indicate by check mark if the registrant ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy, resulting in heart failure.AstraZeneca Plc‘s AZN Alexion will be responsible ...

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Astrazeneca (AZN), and highlights the potential misalignment of interests between brokerage analysts and retail investors [1][5][10]. Brokerage Recommendations - Astrazeneca has an average brokerage recommendation (ABR) of 1.38, indicating a position between Strong Buy and Buy, based on recommendations from 16 brokerage firms [2]. - Out of the 16 recommendations, 13 are Strong Buy, accounting for 81.3% of all recommendations [2]. Limitations of Brokerage Recommendations - Solely relying on brokerage recommendations for investment decisions may not be advisable, as studies suggest they have limited success in guiding investors towards stocks with high price appreciation potential [5]. - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, with five "Strong Buy" recommendations for every "Strong Sell" [6][10]. Zacks Rank Comparison - Zacks Rank, a proprietary stock rating tool, categorizes stocks from Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell) and is based on earnings estimate revisions, making it a more effective indicator of near-term stock performance [8][11]. - The Zacks Rank is updated more frequently than the ABR, reflecting timely changes in earnings estimates, which are crucial for predicting future stock prices [12]. Current Earnings Outlook for Astrazeneca - The Zacks Consensus Estimate for Astrazeneca's current year earnings has decreased by 0.6% over the past month to $4.49, indicating growing pessimism among analysts regarding the company's earnings prospects [13]. - This decline in earnings estimates has resulted in a Zacks Rank 4 (Sell) for Astrazeneca, suggesting caution despite the Buy-equivalent ABR [14].

Core Insights - Lunit is set to present a deep learning study on predicting EGFR mutations in non-small cell lung cancer (NSCLC) at the AACR Annual Meeting 2025, showcasing the Lunit SCOPE Genotype Predictor in collaboration with AstraZeneca [1][2] Group 1: Study Details - The study utilizes the largest and most diverse training dataset to date, comprising over 12,000 pathology slides, including more than 4,500 EGFR-mutated and over 7,500 wild-type samples from NSCLC patients across multiple countries [3] - The AI model demonstrated consistent performance across various clinical variables, including specimen types, EGFR mutation subtypes, slide scanners, and scan magnifications, indicating its potential for real-world application [4] Group 2: Industry Impact - The collaboration aims to enhance the efficiency of EGFR mutation testing, which is critical for determining treatment options for NSCLC patients, addressing logistical and resource constraints that have previously limited testing [3][5] - The successful application of AI in this context could enable clinicians to prioritize molecular testing, ensuring timely access to targeted therapies for patients [5] Group 3: Company Background - Lunit, founded in 2013, focuses on AI-powered medical image analytics and biomarker analysis to improve cancer diagnosis and treatment, with its FDA-cleared Lunit INSIGHT suite serving over 4,800 medical institutions globally [7] - The company has a strong presence in the medical community, with clinical studies published in prestigious journals and presented at major global conferences [7]

Core Viewpoint - AstraZeneca has shown strong financial performance despite facing challenges, making it a potentially attractive investment opportunity for long-term holders [2][4][5]. Financial Performance - AstraZeneca's revenue increased by 18% year over year to $54.1 billion, with adjusted earnings per share rising 13% to $8.21 [4]. - The company has a diversified lineup, with 14 medicines each generating over $1 billion in sales last year [9]. Challenges and Risks - AstraZeneca faced executive arrests and an insurance fraud investigation in China, which impacted its stock price [3][5]. - The company may incur fines related to illegal drug importation in China, potentially amounting to $4.5 million, which is manageable given its revenue scale [6]. - Two patent expirations in the U.S. for Soliris and Brilinta are anticipated, but their impact on overall growth is expected to be minimal [7][8]. Growth Potential - AstraZeneca's pipeline includes promising new therapies, such as the investigational oral GLP-1 therapy AZD5004, which is in early clinical trials [10]. - The company is actively pursuing various therapeutic areas, with over a dozen regulatory approvals or clinical trial readouts expected [11]. Investment Outlook - Despite short-term headwinds, AstraZeneca's stock has performed well, indicating investor confidence [12].

Group 1 - AstraZeneca will invest $2.5 billion in a research and development center in Beijing, China [1] - The new hub is expected to increase AstraZeneca's workforce in Beijing to approximately 1,700 employees [1] - The announcement coincides with an upcoming interview of AstraZeneca's CEO Pascal Soriot on CNBC International [1]

// 热点聚焦 // 1、 我国将多措并举大力提振消费。相关职能部门正积极加紧制定育儿补贴、劳动工资等政策。 央行将会同金融监管等部门，研究出台金融支持扩大消费 的专门文件。商务部将加力扩围实施消费品以旧换新，开展汽车流通消费改革试点。财政部、人社部将在补助、稳就业等方面多措并举，提升居民消费能 力。市场监管总局将严格开展监管执法，针对价格欺诈等市场顽疾开展专项整治行动。 2、 国家统计局70城房价数据出炉，一线城市新房价格环比继续上涨，二线城市新房价格环比由上月上涨0.1%转为持平。2月份，新房价格环比上涨城市 为18个，较上月减少6个，其中南京连续3个月领涨全国； 二手房价格环比上涨城市有3个，比上月减少4个，深圳领涨全国。 3、国家统计局公布数据显示， 今年前两个月，我国工业增加值、服务业生产指数、社会消费品零售总额、固定资产投资分别同比增长5.9%、5.6%、4% 和4.1%，比上年全年分别加快0.1、0.4、0.5和0.9个百分点。 房地产开发投资同比下降9.8%，新建商品房销售面积下降5.1%，均降幅收窄。 // 环球市场 // 1、 美国三大股指全线收涨， 道指涨0.85%报41841.63点， ...